Copyright © 2019. Inderes Oy. All rights reserved.

Genovis AB

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
30.4.
2021

Redeye provides a follow-up note to Genovis Q1'21 report, with updated estimates and valuation.

Muut analyysit
29.4.
2021

Redeye’s first impression of Genovis Q1’21 is that it is a pretty solid report in the core business, given that customer activity remains regionally sluggish due to the pandemic.

Tiedotteet
29.4.
2021

First quarter in brief

  •                     Net sales rose by 37 percent to SEK 15,723 (11,475) thousand. Organic growth was 21%.

  •                     Gross profit was SEK 15,017 (10,977) thousand.

  •                     Operating profit before depreciation and amortization (EBITDA) totaled SEK 1,958 (loss: 847) thousand.

  •                     Operating profit totaled SEK 551 (loss: 1,889) thousand.

  •                     Comprehensive income for the period totaled SEK 1,607 (loss: 1,915) thousand.

Tiedotteet
28.4.
2021

Genovis 2020 Annual Report is now available in Swedish and English at our website.

To read or download the annual report in Swedish, go to:

https://investor.genovis.com/wp-content/uploads/genovis-arsredovisning-2020.pdf

To read or download the annual report in English, go to:

https://investor.genovis.com/wp-content/uploads/genovis-annual-report-2020.pdf

Tiedotteet
14.4.
2021

The shareholders of Genovis AB, corporate identity no 556574-5345, are hereby given notice of the Annual General Meeting on Thursday, May 20, 2021.

Tiedotteet
13.4.
2021
Firms Working to Co-Develop Automated Biotherapeutic Characterization Workflows, Combining Genovis SmartEnzymes™ and Waters LC-MS Instrumentation.
  • Collaboration intended to bring speed and simplicity to bio-characterization workflows

  • Automated workflows to cut the time and effort required to monitor critical quality attributes of biotherapeutics in regulated laboratories

  • Waters and Genovis share mutual goal to advance the science behind the analysis of glycoproteins and protein therapeutics

Tiedotteet
29.3.
2021

Genovis AB's (publ) Chief Financial Officer (CFO) Johny Humaloja has resigned from his position to take on new challenges.

Johny has been employed by Genovis since 2019 and he will continue in his current role during the notice period. A process to recruit a new CFO will be initiated immediately.

"During his time at Genovis, Johny has contributed to the development of the Group's financial management. I would like to thank him for his contribution to Genovis and wish him good luck in his new endeavors," says Fredrik Olsson, CEO of Genovis

Tiedotteet
2.3.
2021

The Nomination Committee proposes that Genovis should expand its Board of Directors at the 2021 Annual General Meeting and proposes Steve Jordan to be elected as a new board member.

Tiedotteet
11.2.
2021

Report for the fourth quarter of 2020          

Tiedotteet
10.12.
2020

Genovis AB and Glykos Finland Oy have today entered into a licensing and supply agreement for state-of-the-art linker-payload technologies to be combined with the site-specific antibody conjugation platform offered by Genovis.

Genovis AB